3 per 100 person-years in 2002 to 14.

AIDS mortality in China drops by nearly two thirds since 2002 when country began free of charge treatment program China’s HIV/AIDS-related mortality has dropped from 39.3 per 100 person-years in 2002 to 14. This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent information service, is a scheduled system of the Kaiser Family members Foundation, a nonpartisan healthcare policy research corporation unaffiliated with Kaiser Permanente.Thai, M.D., Ly V. Chuong, M.D., Dinh X. Sinh, M.D., Van A. Duong, B.Sc., Thu N. Hoang, M.Sc., Pham T. Diep, B.Sc., James I. Campbell, M.I.B.M.S., Tran P.M. Sieu, M.D., Stephen G. Baker, Ph.D., Nguyen V.V. Chau, M.D., Ph.D., Tran T. Hien, M.D., Ph.D., David G. Lalloo, M.D., and Jeremy J. Farrar, M.D., D.Phil.: Combination Antifungal Therapy for Cryptococcal Meningitis There are approximately 1 million cases of cryptococcal meningitis annually and 625,000 deaths.1 Treatment guidelines suggest induction therapy with amphotericin B deoxycholate and flucytosine .2 However, this treatment has not been shown to reduce mortality, in comparison with amphotericin B monotherapy.2,3 Flucytosine is generally unavailable where the disease burden is best, and concerns about price and side effects have got limited its use in resource-poor settings.4 Fluconazole is readily available, is connected with low prices of adverse events, and has great penetration into cerebrospinal fluid , nonetheless it is connected with poor outcomes when used while monotherapy for cryptococcal meningitis.2 Its basic safety profile, low cost, and availability help to make it an attractive alternative to flucytosine for mixture therapy with amphotericin B, and it is recommended as an alternative in the guidelines.2 However, when this combination was used in conventional doses , it didn’t enhance the rate of yeast clearance from the CSF, in a study not powered for medical end points.5 Increased doses of amphotericin B and fluconazole independently result in improved rates of yeast clearance.6,7 To our knowledge, these increased doses have not been tested in combination.8 In Asia, many individuals receive treatment with amphotericin B monotherapy for 2 to 4 weeks, followed by fluconazole at a dose of 400 mg each day until the end of week 10.